HIV Diagnostics Market to Grow with a CAGR of 8.68% through 2030

Rising prevalence of HIV infections in developing nations and growing public-private partnerships to enhance diagnostic infrastructure, is expected to drive the Global HIV Diagnostics Market growth in the forecast period, 2026-2030

According to TechSci Research report, “HIV Diagnostics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global HIV Diagnostics Market stood at USD 4.53 Billion in 2024 and is expected to reach USD 7.47 Billion by 2030 with a CAGR of 8.68% during the forecast period. The global HIV diagnostics market is witnessing significant growth, driven by various market drivers that are shaping the industry's landscape. HIV (Human Immunodeficiency Virus) is a major global health concern, and early diagnosis plays a crucial role in managing the disease and preventing its transmission. One of the primary drivers of the global HIV diagnostics market is the increasing prevalence of HIV worldwide. According to the World Health Organization (WHO), approximately 38 million people were living with HIV in 2019. This escalating burden of the disease necessitates more extensive testing and diagnostics, thereby boosting the demand for HIV diagnostic products and services.                   

Recent advancements in diagnostic technologies have significantly improved the accuracy, speed, and accessibility of HIV testing. Innovations such as rapid point-of-care (POC) tests, nucleic acid testing (NAT), and next-generation sequencing (NGS) have enhanced the sensitivity and specificity of HIV diagnostics. These technological advancements not only enable early detection but also simplify testing procedures, making them more user-friendly.

Growing awareness campaigns and government initiatives to promote HIV testing and prevention have contributed to higher testing rates. The increased availability of HIV testing centers, mobile testing units, and home testing kits has made testing more accessible to at-risk populations, including individuals in remote areas and those with limited healthcare access.

Early diagnosis is crucial for timely intervention and access to antiretroviral therapy (ART). Studies have shown that early initiation of treatment can significantly improve the life expectancy and quality of life for individuals living with HIV. Consequently, healthcare providers and governments are emphasizing the importance of early diagnosis, driving the demand for HIV diagnostics. The HIV diagnostics market benefits from continuous investments in research and development (R&D) to develop more accurate and cost-effective testing methods. Companies are focusing on developing innovative diagnostic tools, including advanced antibody assays, viral load tests, and CD4 count tests. These investments are likely to drive market growth in the coming years. Developing regions, particularly in Africa and Asia, are witnessing significant improvements in healthcare infrastructure and access to medical services. These regions carry a substantial burden of HIV cases, leading to a growing demand for diagnostics. Initiatives by international organizations, governments, and NGOs have further enhanced access to HIV testing and treatment, contributing to market growth.                                                                       

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global HIV Diagnostics Market”

The Global HIV Diagnostics Market is segmented into product, test type, mode, end-use, regional distribution, and company.

Based on the Test Type, Antibody Tests emerged as the fastest growing segment in the Global HIV Diagnostics Market during the forecast period. This is due to their rapid turnaround time, cost-effectiveness, and expanding adoption in both clinical and point-of-care settings. Antibody tests are among the first-line diagnostics used to detect HIV-specific antibodies produced by the body in response to the virus. Their ease of use, minimal infrastructure requirements, and ability to deliver accurate results within minutes make them ideal for large-scale screening programs, particularly in low-resource settings where access to advanced laboratory infrastructure is limited. The growing demand for early HIV detection, particularly among high-risk populations, has further fueled the adoption of antibody-based diagnostics. Governments and global health organizations are increasingly promoting routine HIV screening and awareness campaigns, driving higher testing volumes.

Based on the Region, Asia-Pacific emerged as the fastest growing region in the Global HIV Diagnostics Market during the forecast period. The region is benefiting from significant advancements in diagnostic technology and increased investments by domestic and international players aiming to strengthen the supply chain and local manufacturing of diagnostic kits. The presence of a large and diverse population base, combined with the growing adoption of self-testing and home-based HIV diagnostics, is fueling market expansion. Countries in the region are rapidly adopting rapid antibody and antigen tests, especially in urban and semi-urban areas, where access to healthcare is improving. Furthermore, partnerships between governments and private diagnostic companies are leading to the introduction of innovative, low-cost, and easy-to-use testing solutions tailored to local needs. Increasing integration of HIV testing with other disease screening programs, such as for tuberculosis and sexually transmitted infections (STIs), is helping to streamline diagnostics in public health settings. As digital healthcare gains traction, the use of telemedicine platforms to support HIV counseling, testing, and result delivery is also growing.

Major companies operating in Global HIV Diagnostics Market are:

• Thermo Fisher Scientific, Inc.
• Alere Inc.
• Abbott Laboratories Inc.
• Bristol-Myers Squibb Company
• Janssen Global Services, LLC
• Gilead Sciences, Inc.
• Merck & Co. Inc.
• VIIV Healthcare
• Beckman Coulter, Inc.
• Sysmex Europe SE
• Zyomtronix, Inc.
• Mylan N.V.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare GmbH

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Global HIV Diagnostics Market is expanding due to the growing adoption of integrated diagnostic platforms that allow simultaneous testing for multiple infectious diseases, including HIV, tuberculosis, and hepatitis. This convergence of testing capabilities not only streamlines clinical workflows but also enhances early detection rates and reduces diagnostic delays in high-burden regions. These platforms are increasingly being deployed in public health systems and point-of-care settings, improving access and efficiency of HIV screening services, especially in resource-limited environments. The integration of multiplex diagnostics supports comprehensive patient assessment and better allocation of healthcare resources, thereby contributing to improved disease management and broader public health outcomes.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“HIV Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Consumables, Instruments, Software and Services), By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others), By Mode (Self-Test, Lab-based), By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global HIV Diagnostics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global HIV Diagnostics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com